Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 17 studies | 32% ± 12% | |
lung | 16 studies | 31% ± 14% | |
intestine | 11 studies | 27% ± 12% | |
kidney | 7 studies | 26% ± 3% | |
liver | 7 studies | 27% ± 18% | |
eye | 6 studies | 27% ± 14% | |
lymph node | 6 studies | 30% ± 4% | |
brain | 6 studies | 25% ± 4% | |
pancreas | 4 studies | 40% ± 15% | |
bone marrow | 4 studies | 24% ± 4% | |
uterus | 4 studies | 35% ± 17% | |
breast | 4 studies | 30% ± 4% | |
placenta | 3 studies | 39% ± 16% | |
prostate | 3 studies | 27% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 3610.10 | 1445 / 1445 | 100% | 141.11 | 183 / 183 |
intestine | 100% | 3434.59 | 966 / 966 | 100% | 200.90 | 527 / 527 |
ovary | 100% | 2195.35 | 180 / 180 | 100% | 139.99 | 430 / 430 |
stomach | 100% | 2519.11 | 359 / 359 | 100% | 178.83 | 286 / 286 |
breast | 100% | 3163.96 | 459 / 459 | 100% | 129.21 | 1114 / 1118 |
brain | 100% | 2840.96 | 2632 / 2642 | 100% | 133.73 | 705 / 705 |
skin | 100% | 4461.85 | 1809 / 1809 | 100% | 143.85 | 470 / 472 |
prostate | 100% | 2417.13 | 245 / 245 | 99% | 110.06 | 499 / 502 |
uterus | 100% | 2609.80 | 170 / 170 | 99% | 119.15 | 456 / 459 |
bladder | 100% | 3380.19 | 21 / 21 | 99% | 154.91 | 500 / 504 |
thymus | 100% | 2382.38 | 652 / 653 | 99% | 85.94 | 601 / 605 |
lung | 99% | 2482.17 | 573 / 578 | 100% | 123.20 | 1152 / 1155 |
pancreas | 99% | 1730.13 | 325 / 328 | 99% | 72.85 | 177 / 178 |
kidney | 100% | 3882.76 | 89 / 89 | 98% | 88.48 | 883 / 901 |
adrenal gland | 100% | 5597.07 | 258 / 258 | 97% | 77.03 | 223 / 230 |
liver | 100% | 2807.93 | 225 / 226 | 97% | 74.49 | 394 / 406 |
lymph node | 0% | 0 | 0 / 0 | 100% | 212.95 | 29 / 29 |
muscle | 100% | 4095.22 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 3127.48 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 126.32 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 42.26 | 1 / 1 |
adipose | 100% | 3010.16 | 1203 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2336.75 | 1331 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 122.84 | 78 / 80 |
heart | 96% | 3006.51 | 830 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 84% | 3713.10 | 779 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006397 | Biological process | mRNA processing |
GO_0030449 | Biological process | regulation of complement activation |
GO_0045087 | Biological process | innate immune response |
GO_1901165 | Biological process | positive regulation of trophoblast cell migration |
GO_0006974 | Biological process | DNA damage response |
GO_0032695 | Biological process | negative regulation of interleukin-12 production |
GO_0045785 | Biological process | positive regulation of cell adhesion |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0039536 | Biological process | negative regulation of RIG-I signaling pathway |
GO_0039534 | Biological process | negative regulation of MDA-5 signaling pathway |
GO_0006955 | Biological process | immune response |
GO_2000510 | Biological process | positive regulation of dendritic cell chemotaxis |
GO_0008380 | Biological process | RNA splicing |
GO_0006958 | Biological process | complement activation, classical pathway |
GO_0050687 | Biological process | negative regulation of defense response to virus |
GO_0042256 | Biological process | cytosolic ribosome assembly |
GO_0043491 | Biological process | phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_0090023 | Biological process | positive regulation of neutrophil chemotaxis |
GO_0006915 | Biological process | apoptotic process |
GO_0070131 | Biological process | positive regulation of mitochondrial translation |
GO_0032689 | Biological process | negative regulation of type II interferon production |
GO_0051897 | Biological process | positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_1900026 | Biological process | positive regulation of substrate adhesion-dependent cell spreading |
GO_0048025 | Biological process | negative regulation of mRNA splicing, via spliceosome |
GO_0043065 | Biological process | positive regulation of apoptotic process |
GO_2000042 | Biological process | negative regulation of double-strand break repair via homologous recombination |
GO_0005730 | Cellular component | nucleolus |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0005739 | Cellular component | mitochondrion |
GO_0009986 | Cellular component | cell surface |
GO_0005829 | Cellular component | cytosol |
GO_0005759 | Cellular component | mitochondrial matrix |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0008134 | Molecular function | transcription factor binding |
GO_0030984 | Molecular function | kininogen binding |
GO_0004857 | Molecular function | enzyme inhibitor activity |
GO_0031690 | Molecular function | adrenergic receptor binding |
GO_0003714 | Molecular function | transcription corepressor activity |
GO_0003729 | Molecular function | mRNA binding |
GO_0097177 | Molecular function | mitochondrial ribosome binding |
GO_0001849 | Molecular function | complement component C1q complex binding |
GO_0060703 | Molecular function | deoxyribonuclease inhibitor activity |
GO_0005515 | Molecular function | protein binding |
GO_0005540 | Molecular function | hyaluronic acid binding |
Gene name | C1QBP |
Protein name | Complement C1q binding protein Complement component 1 Q subcomponent-binding protein, mitochondrial (ASF/SF2-associated protein p32) (Glycoprotein gC1qBP) (C1qBP) (Hyaluronan-binding protein 1) (Mitochondrial matrix protein p32) (gC1q-R protein) (p33) (SF2AP32) Complement component 1 Q subcomponent-binding protein, mitochondrial |
Synonyms | SF2P32 GC1QBP hCG_2040042 HABP1 |
Description | FUNCTION: Is believed to be a multifunctional and multicompartmental protein involved in inflammation and infection processes, ribosome biogenesis, protein synthesis in mitochondria, regulation of apoptosis, transcriptional regulation and pre-mRNA splicing. At the cell surface is thought to act as an endothelial receptor for plasma proteins of the complement and kallikrein-kinin cascades. Putative receptor for C1q; specifically binds to the globular 'heads' of C1q thus inhibiting C1; may perform the receptor function through a complex with C1qR/CD93. In complex with cytokeratin-1/KRT1 is a high affinity receptor for kininogen-1/HMWK. Can also bind other plasma proteins, such as coagulation factor XII leading to its autoactivation. May function to bind initially fluid kininogen-1 to the cell membrane. The secreted form may enhance both extrinsic and intrinsic coagulation pathways. It is postulated that the cell surface form requires docking with transmembrane proteins for downstream signaling which might be specific for a cell-type or response. By acting as C1q receptor is involved in chemotaxis of immature dendritic cells and neutrophils and is proposed to signal through CD209/DC-SIGN on immature dendritic cells, through integrin alpha-4/beta-1 during trophoblast invasion of the decidua, and through integrin beta-1 during endothelial cell adhesion and spreading. Signaling involved in inhibition of innate immune response is implicating the PI3K-AKT/PKB pathway. Required for protein synthesis in mitochondria . In mitochondrial translation may be involved in formation of functional 55S mitoribosomes; the function seems to involve its RNA-binding activity. May be involved in the nucleolar ribosome maturation process; the function may involve the exchange of FBL for RRP1 in the association with pre-ribosome particles. Involved in regulation of RNA splicing by inhibiting the RNA-binding capacity of SRSF1 and its phosphorylation. Is required for the nuclear translocation of splicing factor U2AF1L4. Involved in regulation of CDKN2A- and HRK-mediated apoptosis. Stabilizes mitochondrial CDKN2A isoform smARF. May be involved in regulation of FOXC1 transcriptional activity and NFY/CCAAT-binding factor complex-mediated transcription. May play a role in antibacterial defense as it can bind to cell surface hyaluronan and inhibit Streptococcus pneumoniae hyaluronate lyase. May be involved in modulation of the immune response; ligation by HCV core protein is resulting in suppression of interleukin-12 production in monocyte-derived dendritic cells. Involved in regulation of antiviral response by inhibiting RIGI- and IFIH1-mediated signaling pathways probably involving its association with MAVS after viral infection. .; FUNCTION: (Microbial infection) Involved in HIV-1 replication, presumably by contributing to splicing of viral RNA. .; FUNCTION: (Microbial infection) In infection processes acts as an attachment site for microbial proteins, including Listeria monocytogenes internalin B (InlB) and Staphylococcus aureus protein A. .; FUNCTION: (Microbial infection) Involved in replication of Rubella virus. . |
Accessions | ENST00000576122.1 ENST00000574444.5 A0A0G2JLC0 I3L3Q7 ENST00000570805.1 ENST00000225698.8 I3L3B0 Q07021 |